Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
RESEARCH TOOLSreports
Century Therapeutics (IPSC) Stock Price & Analysis
117 Followers
IPSC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.28 - $5.51
Previous Close$2.5
Volume121.76K
Average Volume (3M)222.28K
Market Cap
$211.25M
Enterprise Value$85.17M
Total Cash (Recent Filing)$172.74M
Total Debt (Recent Filing)$46.66M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Aug 08, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.22
Shares Outstanding82,847,375
10 Day Avg. Volume344,231
30 Day Avg. Volume222,283
Standard Deviation0.30
R-Squared0.06
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.08
Price to Sales (P/S)45.58
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue38.11
Enterprise Value/Gross Profit38.11
Enterprise Value/Ebitda-0.70
Forecast
1Y Price Target
$11.50Price Target Upside360.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Century Therapeutics News
Bulls Say, Bears Say
Bulls Say
Acquisition And ExpansionCentury’s acquisition of Clade Therapeutics has bolstered their preclinical pipeline and discovery efforts.
Financial StrengthCentury is well positioned to advance their suite of engineered iPSC-derived NK and T cell therapies with significant cash reserves and recent private placement proceeds.
Safety And EfficacyUpdated Phase 1 data suggest higher dose levels are safe, with implications for autoimmune dosing.
Bears Say
Financial PerformanceCentury reported a net loss of $0.45 per share, which is close to the estimated net loss of $0.52 per share.
Product PerformanceThere is not enough data to be confident that CNTY-101 could replace approved autologous CAR-T therapies in B cell malignancies.
Stock Price TargetThe 12-month price target for the stock has been decreased to $11 from the prior $13.
---
Ownership Overview
45.43% Insiders
6.16% Mutual Funds
20.49% Other Institutional Investors
27.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $1.28 and its highest was $5.51 in the past 12 months.
What is Century Therapeutics’s market cap?
Currently, no data Available
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on May 09, 2024. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.513 by $0.063.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -$0.46.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 84,500,780 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.513. Following the earnings report the stock price went down -0.977%.
Which hedge fund is a major shareholder of Century Therapeutics?
Among the largest hedge funds holding Century Therapeutics’s share is Baker Bros Advisors LP. It holds Century Therapeutics’s shares valued at 3M.
---
Century Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.50 (360.00% Upside)
$11.50 (360.00% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 66%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $3.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.38%
12-Months-Change
Fundamentals
Return on Equity
-58.66%
Trailing 12-Months
Asset Growth
-23.61%
Trailing 12-Months
Company Description
Century Therapeutics
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
---
IPSC Stock 12 Month Forecast
Average Price Target
$11.50
▲(360.00% Upside)
Technical Analysis
Best Analysts Covering IPSC
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-22.68%
reiterated a buy rating 2 months ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -22.68% per trade.
---